Ketamine - Articles - Page 2 | CARLAT PUBLISHING

CARLAT WEBINAR

Ketamine and the Evolving Psychopharmacologic Pipeline for Depression

December 8, 2023

0.50 CME Credits. Robert Meisner, MD, explores the latest developments in psychiatric treatment with ketamine and esketamine, including their differences and emerging insights for clinicians.

Screen Shot 2023-11-12 at 1.13.49 PM.png

Ketamine: Six New Findings Part 2

November 13, 2023

Chris Aiken, MD and Kellie Newsome, PMHNP

New research brings clarity to the big ketamine questions. How does it compare to ECT and antipsychotics? How much of it is placebo? Which is more effective – ketamine or esketamine? How do you sustain the benefits? Does it work better with psychotherapy?

Research Update

How Does Ketamine Compare to ECT in Treatment-Resistant Depression?

November 9, 2023

Awais Aftab, MD.

Awais Aftab, MD. Dr. Aftab has no financial relationships with companies related to this material.

This study made headlines with its surprising results, but you’ll want to read the fine print to understand how it informs practice.

Screen Shot 2023-11-05 at 6.56.55 PM.png

Ketamine: Six New Findings Part 1

November 6, 2023

Chris Aiken, MD and Kellie Newsome, PMHNP

New research brings clarity to the big ketamine questions. How does it compare to ECT and antipsychotics? How much of it is placebo? Which is more effective – ketamine or esketamine? How do you sustain the benefits? Does it work better with psychotherapy?

Expert Q&A

Psychedelic-Assisted Psychotherapy

June 1, 2023

Jeffrey Guss, MD

Jeffrey Guss, MD.

Psychiatrist and psychoanalyst. Clinical Assistant Professor of Psychiatry at NYU Grossman School of Medicine. Faculty at the NYU Postdoctoral Program in Psychotherapy and Psychoanalysis.

Dr. Guss has no financial relationships with companies related to this material.

What actually happens during psychedelic psychotherapy? Dr. Guss walks us through the steps.
1) preparation, 2) dosing, and 3) integration, where the insights gained from psychedelic experiences are turned into action in the real world.

Clinical Update

A Psychedelic Primer

June 1, 2023

Chris Aiken, MD and Garrett Rossi, MD.

Chris Aiken, MD. Editor-in-Chief of The Carlat Psychiatry Report. Assistant Professor, NYU Langone Department of Psychiatry. Practicing psychiatrist, Winston-Salem, NC.

Garrett Rossi, MD. Inpatient/Consult Attending Psychiatrist, AtlantiCare Regional Medical Center, Pomona, NJ.

The authors have no financial relationships with companies related to this material.

How did a dangerous drug of abuse become a therapeutic panacea?

Ketamine Comes Home

February 26, 2023

Kellie Newsome, PMHNP and Chris Aiken, MD

Online clinics delivered at-home ketamine throughout the pandemic, and we’re just becoming aware of the consequences.

Intravenous Ketamine for Teen Depression

January 31, 2022

Pavan Madan, MD.

Pavan Madan, MD. Dr. Madan has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Ketamine is a hot topic in the treatment of adults with severe depression. But how effective is ketamine in adolescents? This research update looks at some emerging data to help you decide whether off label use of ketamine might be a viable option in teens with severe depression.

Pilot Study of Ketamine vs ECT for Major Depression

September 10, 2021

Michael Posternak, MD.

Michael Posternak, MD. Dr. Posternak has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

The first head-to-head comparison reveals a subtle difference between these two therapies

Psilocybin: The New Holy Grail for the Rapid Relief of Major Depression?

July 14, 2021

Paul Barkopoulos, MD.

Paul Barkopoulos, MD. Dr. Barkopoulos has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Like ketamine, psilocybin works quickly to relieve depression, but it’s not habit-forming and its effects might last longer.